Company Name : Kee Pharma Limited
Address : A-1, Community Centre, Naraina Industrial Area, Phase – II, New Delhi – 110028 (India)
Tel No: 0091-11-51417747, 48, 49, 50
Email : mail@keepharma.com, sales@keepharma.com
Website : http://www.keepharma.com/
Company Profile
Kee Pharma Limited is a well-established Delhi based pharmaceutical company that was started in 1957 by Mr. C.R. Motihar. Today, KPL has a 300 strong work force that is made up of professional and dynamic individuals working together as a team to ensure that KPL is an efficient and professionally run organisation.
Kee Pharma is an Innovative, Dynamic and Caring organisation. We strive to provide the best that modern medicine has to offer be it new dosage forms, revolutionary pharmaceutical molecules or biotechnologically engineered cures. Innovative attitude to life drives us to always look for a better and more effective cure. Our Dynamism allows us to cross our nation’s boundaries and forage into the global market to find these cures. Our Caring outlook makes us ensure that these cures are available to the people of India through an effective and extensive distribution network and careful pricing. Being a well-established 45-year-old company, we have our feet firmly planted on the ground. We know the importance of Quality, Purity and Effectiveness of medicine. Above all else, we know what it takes to achieve all three and we make sure that we do Every person at Kee Pharma understands the importance of quality, purity and effectiveness and in this understanding, knows at the very bottom of his or her heart that – Life matters…People matter
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…